DATA SHEET

1 PRODUCT NAME

Frumil® 40mg/5mg Tablet

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Furosemide (frusemide) 40 mg and Amiloride hydrochloride 5 mg (anhydrous).

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Orange tablets with break-line; FRUMIL on reverse side.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Frumil is indicated for the treatment of cardiac failure, in patients who require diuretics plus potassium supplements, or potassium sparing diuretics.

4.2 DOSE AND METHOD OF ADMINISTRATION

The initial adult dose is one tablet (40 mg furosemide (frusemide) and 5 mg amiloride hydrochloride) to be taken each morning. This may be increased to two tablets daily if the initial response is unsatisfactory. In this case, it is best to divide the dosage into two daily doses, one to be taken in the morning and the other at noon. The total daily dose of amiloride should not exceed 20 mg. The tablets are to be swallowed whole with sufficient amounts of liquid (approximately half a glass). They are best taken on an empty stomach.
4.3 CONTRAINDICATION

Patients with hyperkalemia (serum potassium above 5.5 mmol per litre).

Patients with severe hypokalaemia. However, if hypokalaemia develops during treatment it can usually be corrected without interrupting administration of Frumil (see Section 4.8).

Patients with hypovolaemia or dehydration.

Patients with impaired renal function and a creatinine clearance below 30 mL/min per 1.73 m² body surface area, acute renal failure or anuria.

Patients with severe hyponatraemia.

Patients with pre-comatose and comatose states associated with hepatic encephalopathy.

Patients on concomitant potassium supplements.

Patients who are pregnant or breastfeeding.

Patients with a hypersensitivity to furosemide (frusemide), amiloride, sulfonamides or sulfonamide derivatives, or any of the excipients of Frumil. Patients allergic to sulfonamides (e.g. sulfonamide antibiotics or sulfonylureas) may show cross-sensitivity to furosemide (frusemide).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Hyperkalaemia has been observed in patients receiving amiloride hydrochloride. Furosemide (Frusemide) can cause latent diabetes to become manifest or the insulin requirements of diabetic patients to increase. Patients with prostatic hypertrophy or impairment of micturition are at increased risk of developing acute urinary retention. Serum uric acid levels may rise during treatment with Frumil and an acute attack of gout may be precipitated.

Cephaloridine nephrotoxicity may be increased by concomitant administration of patient diuretics such as Frumil.

Urinary outflow must be secured. In patients with a partial obstruction of urinary outflow (e.g. patients with bladder-emptying disorders, prostatic hyperplasia or narrowing of the urethra), increased production of urine may provoke or aggravate complaints. Thus, these patients require careful monitoring – especially during the initial stages of treatment.

Treatment with Frumil necessitates regular medical supervision. Particularly careful monitoring is required in patients with: hypotension, in patients who would be at particular risk from a pronounced fall in blood pressure (e.g. significant stenoses of the coronary arteries or of the blood vessels supplying the brain), latent or manifest diabetes mellitus, gout, hepatorenal syndrome (i.e. functional renal failure associated with severe liver disease), hypoproteinaemia (e.g. associated with nephrotic syndrome).

All potassium conserving diuretic combinations can cause an abnormal elevation of serum potassium. It is recommended that measurements of potassium are made at appropriate intervals and at time of dosage adjustment, particularly in elderly or diabetic patients and also in patients with confirmed or suspected renal impairment and a creatinine clearance below 60 mL/min per 1.73 m² body surface area as well as in cases where Frumil is taken in combination with certain
other drugs which may lead to an increase in potassium concentration. Warning signs of hyperkalemia include parasthesia, muscular weakness, fatigue, flaccid paralysis extremities, bradycardia, shock, serum potassium and ECG abnormalities. Should hyperkalemia occur, Frumil should be discontinued and measures to reduce plasma potassium may be necessary.

Regular monitoring of serum sodium, potassium and creatinine and blood glucose is generally recommended during Frumil therapy; particularly close monitoring is required in patients at high risk of developing electrolyte imbalances or in case of significant additional fluid loss (e.g. due to vomiting, diarrhoea or intense sweating). Hyponatraemia, hypochloraemia and raised blood urea nitrogen may occur during vigorous diuresis, especially in seriously ill patients. Careful monitoring of serum electrolytes and urea should, therefore, be undertaken in these patients.

Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances must be corrected. This may require temporary discontinuation of Frumil.

The dosage of concurrently administered cardiac glycosides or antihypertensive agents may require adjustment.

Frumil should be discontinued before a glucose tolerance test.

Caution should be exercised and the risks and benefits of combining risperidone with furosemide (frusemide) or other potent diuretics should be considered prior to the decision to treat. In the risperidone placebo-controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide (frusemide) plus risperidone (7.3% ; mean age 89 years, range 75 to 97) compared to treatment with risperidone alone (3.1% ; mean age 84 years, range 70 to 96) or furosemide (frusemide) alone (4.1% ; mean age 80 years, range 67 to 90). Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low doses) was not associated with similar mortality findings. No pathophysiological mechanism has been identified to explain this finding and no consistent pattern for cause of death was observed. Nevertheless, caution is advised. Irrespective of treatment, dehydration was an overall risk factor for mortality and should, therefore, be carefully avoided in elderly patients with dementia.

4.5 INTERACTION WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTION

Combinations that are not recommended
In isolated cases intravenous administration of furosemide (frusemide) within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure and tachycardia. Use of Frumil concomitantly with chloral hydrate is, therefore, not recommended.

Furosemide (Frusemide) may potentiate the ototoxicity of aminoglycosides and other ototoxic drugs. Since this may lead to irreversible damage, these drugs must only be used with furosemide (frusemide) if there are compelling medical reasons.
Precautions for use

There is a risk of ototoxic effects if cisplatin and furosemide (frusemide) are given concomitantly. In addition, nephrotoxicity of cisplatin may be enhanced if furosemide (frusemide) is not given in low doses (eg. 40 mg in patients with normal renal function) and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.

Oral furosemide (frusemide) and sucralfate must not be taken within two hours of each other because sucralfate decreases the absorption of furosemide (frusemide) from the intestine and hence, reduces its effect.

Furosemide (Frusemide) decreases the excretion of lithium salts and may cause increased serum lithium levels, resulting in increased risk of lithium toxicity, including increased risk of cardiotoxic and neurotoxic effects of lithium. Therefore, it is recommended that lithium levels are carefully monitored in patients receiving this combination.

Patients who are receiving diuretics may suffer severe hypotension and deterioration in renal function, including cases of renal failure, especially when an angiotensin converting enzyme inhibitor (ACE inhibitor) or angiotensin II receptor antagonist is given for the first time or for the first time in an increased dose. Consideration must be given to interrupting the administration of furosemide (frusemide) temporarily or at least reducing the dose of furosemide (frusemide) for 3 days before starting treatment with or increasing the dose of an ACE inhibitor or angiotensin II receptor antagonist.

Caution should be exercised and the risks and benefits of treating a patient on risperidone with furosemide (frusemide) or other potent diuretics should be considered prior to the decision to use. See Section 4.4 regarding increased mortality in elderly patients with dementia concomitantly receiving risperidone.

High doses of furosemide (frusemide) may inhibit binding of thyroid hormones to carrier proteins when administered with levothyroxine, and thereby lead to an initial transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. It is recommended that thyroid hormones be monitored.

Take into account

When amiloride is taken in combination with potassium salts, with drugs which reduce potassium excretion, with nonsteroidal anti-inflammatory drugs or with ACE-inhibitors, an increase in potassium concentration and hyperkalaemia may occur.

Concomitant administration of non-steroidal anti-inflammatory drugs including acetylsalicylic acid may reduce the effect of Frumil. In patients with dehydration or hypovolaemia, non-steroidal anti-inflammatory drugs may cause acute renal failure. Salicylate toxicity may be increased by furosemide (frusemide).

Attenuation of the effects of Frumil may occur following concurrent administration of phenytoin. Carbenoxolone, corticosteroids, prolonged use of laxatives or ingestion of liquorice in large amounts may increase the risk of developing hypokalaemia.

Some electrolyte disturbances (eg. hypokalaemia, hypomagnesaemia) due to furosemide (frusemide) may increase the toxicity of certain other drugs (eg. digitalis preparations and drugs inducing QT interval prolongation syndrome). Amiloride may cause raised blood digoxin levels.
If antihypertensive agents, diuretics or other drugs with blood-pressure lowering potential are
given concomitantly with Frumil, a more pronounced fall in blood pressure must be anticipated.

Methotrexate, probenecid and other drugs which, like furosemide (frusemide), undergo significant
renal tubular secretion may reduce the effects of furosemide (frusemide). Conversely furosemide
(frusemide) may decrease renal elimination of these drugs. In the case of high dose treatment (in
particular of both furosemide (frusemide) and the other drugs), this may lead to an increased risk
of adverse effects due to furosemide (frusemide) or the concomitant medication.

The effect of anti-diabetics drugs and blood pressure-increasing sympathomimetics (eg.
adrenaline (epinephrine), noradrenaline (norepinephrine)) may be reduced. The effects of curare-
type muscle relaxants or of theophylline may be increased.

The harmful effects of nephrotoxic drugs on the kidney may be increased by furosemide
(frusemide).

Impairment of renal function may develop in patients receiving concurrent treatment with
furosemide (frusemide) and high doses of certain cephalosporins.

Concomitant use of ciclosporin A and furosemide (frusemide) is associated with increased risk of
gouty arthritis secondary to furosemide (frusemide)-induced hyperuricemia and ciclosporin
impairment of renal urate excretion.

Patients who were at high risk for radiocontrast nephropathy treated with furosemide (frusemide)
experienced a higher incidence of deterioration in renal function after receiving radiocontrast
compared to high-risk patients who received only intravenous hydration prior to receiving
radiocontrast.

Use in Children

No experience is available regarding the use of Frumil in children.

4.6 FERTILITY, PREGNANCY AND LACTATION

Use in Pregnancy

Frumil must not be taken during Pregnancy.

Use in Lactation

The safety of Frumil in lactation has not been established; however, furosemide (frusemide)
passes into breast milk and may partially inhibit lactation. The use of Frumil in lactating mothers
should be avoided.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Some adverse effects (eg. a pronounced fall in blood pressure) may impair the patient’s ability to
concentrate and react, and therefore, constitute a risk in situations where these abilities are of
special importance eg. operating a vehicle or machinery.
4.8 UNDESIRABLE EFFECTS

Blood and the lymphatic system disorders
Thrombocytopenia, leucopenia, agranulocytosis, aplastic anaemia or haemolytic anaemia, eosinophilia, haemoconcentration.

Immune system disorders
Severe anaphylactic or anaphylactoid reactions (e.g. with shock). Cases of exacerbation or activation of systemic lupus erythematosus have been reported.

Metabolism and nutrition disorders
The two active ingredients exert opposing influences on potassium excretion. The serum potassium concentration may decrease, especially at the commencement of treatment, although, particularly as treatment is continued, the potassium concentration may increase (owing to the later onset of action of amiloride) especially in patients with impairment of renal function.

Electrolyte disturbances (including symptomatic), metabolic alkalosis due to furosemide (frusemide), metabolic acidosis due to amiloride, dehydration and hypovolaemia especially in elderly patients, increases in blood creatinine, increase in blood cholesterol and triglyceride, hypernatremia, hypochloremia, hypokalaemia increase in blood uric acid and attacks of gout, glucose tolerance impaired. Latent diabetes mellitus may become manifest (see Section 4.4). Hypocalcaemia, hypomagnesemia, blood urea increased.

Pseudo-Bartter syndrome in the context of misuse and/or long-term use of furosemide (frusemide) has been reported.

Nervous system disorders
Paraesthesia, hepatic encephalopathy in patients with hepatocellular insufficiency.

Headache, dizziness, fainting or loss of consciousness have been reported.

Ear and labyrinth disorders
Hearing disorders, although usually transitory, particularly in patients with renal failure, hypoproteinaemia (e.g. in nephritic syndrome). Cases of Deafness, sometimes irreversible have been reported after administration of furosemide (frusemide). Tinnitus has also been reported.

Vascular disorders
Hypotension including orthostatic hypotension, thrombosis, vasculitis.

Gastrointestinal disorders
Nausea, vomiting, diarrhoea, acute pancreatitis.

Hepato-biliary disorders
Cholestasis, increase in liver transaminases.

Skin and subcutaneous tissue disorders
Pruritus, urticaria, rashes, dermatitis bullous, erythema multiforme, pemphigoid, dermatitis exfoliative, purpura, photosensitivity reaction. Stevens-Johnson syndrome, toxic epidermal necrolysis. AGEP (acute generalized exanthematous pustulosis) and DRESS (Drug rash with
eosinophilia and systemic symptoms), lichenoid reactions has been reported with the use of products containing furosemide (frusemide).

**Musculoskeletal and connective tissue disorders**

Cases of rhabdomyolysis have been reported, often in the context of severe hypokalaemia (see Section 4.3).

**Renal and urinary disorders**

Urine sodium increase, urine chloride increase, urine retention (in patients with a partial obstruction of urinary outflow), tubulointerstitial nephritis, renal failure, nephrocalcinosis/nephrolithiasis in premature infants.

**General disorders and administration site conditions**

Fever

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/.

### 4.9 OVERDOSE

**Signs and Symptoms**

The clinical picture in acute or chronic overdose depends primarily on the extent and consequences of electrolyte and fluid loss eg. hypovolaemia, dehydration, haemoconcentration, cardiac arrhythmias (including A-V block and ventricular fibrillation). Symptoms of these disturbances include severe hypotension (progressing to shock), acute renal failure, thrombosis, delirious states, flaccid paralysis, apathy and confusion.

**Treatment**

Treatment of over-dosage should be aimed at reversing the dehydration and correcting electrolyte imbalance, particularly hyperkalaemia. Together with the prevention and treatment of serious complications resulting from such disturbances and of other effects on the body, this corrective action may necessitate general and specific intensive medical monitoring and therapeutic measures. Attempts should be made to limit further systemic absorption of the active ingredient. Treatment is symptomatic and supportive. If hyperkalaemia is seen, appropriate measures to reduce it must be instituted.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).
5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

ATC code: CO3C A01

Frumil is a potassium sparing diuretic which combines the potent natriuretic effect of furosemide (frusemide) with the potassium-conserving property of amiloride hydrochloride. The administration of high ceiling diuretics such as furosemide (frusemide) can result in a significant increase in potassium excretion, which may lead to hypokalaemia or metabolic alkalosis. When combined with amiloride, the amount of potassium excreted is decreased and the need for potassium supplements is eliminated. Moreover, the diuresis produced by furosemide (frusemide) is enhanced with amiloride if given in combination.

Furosemide (frusemide) acts primarily to inhibit electrolyte reabsorption in the ascending limb of the Loop of Henle; this action has also been observed in the proximal tubule. Excretion of sodium, potassium and chloride ions is increased and water excretion enhanced. Diuresis is observed within 1 hour of administration and lasts 4-6 hours. Amiloride hydrochloride acts in the distal convoluted tubule to inhibit the exchange of sodium and potassium ions and therefore to mildly increase the natriuretic effect whilst conserving potassium.

Chloride excretion is little affected by amiloride. Diuresis occurs within 2 hours of administration of amiloride, with peak effect at 6-10 hours; the action lasts for 24 hours.

Clinical studies have indicated that Frumil consistently maintains plasma potassium levels within the normal range. The diuretic and natriuretic activity of Frumil is greater and more prolonged than furosemide (frusemide) alone. Diuresis was observed within 2 hours and lasted for 24 hours.

5.2 PHARMACOKINETIC PROPERTIES

Furosemide:

Approximately 65% of the dose is absorbed after oral administration. The plasma half-life is biphasic with a terminal elimination phase of about 1½ hours. Furosemide is up to 99% bound to plasma proteins and is mainly excreted in the urine, largely unchanged, but also excreted in the bile, non-renal elimination being considerably increased in renal failure. Furosemide crosses the placental barrier and is excreted in the milk.

Amiloride:

Approximately 50% of the dose is absorbed after oral administration and peak serum concentrations are achieved by about 3 - 4 hours. The serum half-life is estimated to be about 6 hours. Amiloride is not bound to plasma proteins. Amiloride is not metabolised and is excreted unchanged in the urine.
5.3 PRECLINICAL SAFETY DATA

No further relevant information other than that which is included in the other sections of the Data Sheet.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Each tablet also contains lactose monohydrate, maize starch, microcrystalline cellulose, sodium starch glycollate, silicon dioxide, purified talc, magnesium stearate, sunset yellow FCF.

6.2 INCOMPATIBILITIES

Not applicable

6.3 SHELF LIFE

36 months

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C.

6.5 NATURE AND CONTENTS OF CONTAINER

Calendar packs of 28 tablets (2 x 14 blisters)

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

No special requirements

7 MEDICINE SCHEDULE

Prescription Medicine

8 SPONSOR

sanofí-aventis new zealand limited
Level 8, 56 Cawley Street
9 DATE OF FIRST APPROVAL

14 July 1988

10 DATE OF REVISION OF THE TEXT

18 September 2017

® Trademark

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Strength dosage form added to product name</td>
</tr>
<tr>
<td>2</td>
<td>Reference to full list of excipients</td>
</tr>
<tr>
<td>4.3</td>
<td>Reference to section headings changed</td>
</tr>
<tr>
<td>4.5</td>
<td>Reference to section headings changed</td>
</tr>
<tr>
<td>4.5</td>
<td>Other active ingredient names harmonised</td>
</tr>
<tr>
<td>4.8</td>
<td>Headings re-ordered to match System Organ Class list, wording changed to match CCDS</td>
</tr>
<tr>
<td>4.8</td>
<td>Spelling errors corrected</td>
</tr>
<tr>
<td>4.8</td>
<td>Reference to section headings changed</td>
</tr>
<tr>
<td>4.8</td>
<td>Additional adverse effects added: Renal failure and lichenoid reactions</td>
</tr>
<tr>
<td>4.8</td>
<td>Statement added about reporting of adverse effects</td>
</tr>
<tr>
<td>4.9</td>
<td>Poisons information updated</td>
</tr>
<tr>
<td>5.1</td>
<td>ATC Code added</td>
</tr>
<tr>
<td>5.2</td>
<td>Pharmacokinetic properties added from UK SPC 01 Sep 16</td>
</tr>
<tr>
<td>5.3</td>
<td>Preclinical safety data statement added</td>
</tr>
<tr>
<td>6.2</td>
<td>Incompatibilities statement added</td>
</tr>
<tr>
<td>6.3</td>
<td>Shelf life added</td>
</tr>
<tr>
<td>6.6</td>
<td>No special precautions for disposal</td>
</tr>
<tr>
<td>8</td>
<td>Toll Free number added</td>
</tr>
<tr>
<td>9</td>
<td>Date of first approval added</td>
</tr>
<tr>
<td>10</td>
<td>Date of revision of the text updated</td>
</tr>
</tbody>
</table>